Primary Publicaton: NEC2

 

This randomized phase II study demonstrated that the addition of bevacizumab to everolimus is associated with higher tumor response rates and improved progression-free survival in patients with advanced pancreatic neuroendocrine tumors. The higher rate of treatment-associated adverse events associated with the combination of bevacizumab and everolimus compared to everolimus alone precluded further investigation of this combination. Nevertheless, the encouraging tumor response rate associated with this combination suggest that its use may still be reasonable in patients with high tumor burden. Continued investigation of bevacizumab and similar agents targeting the VEGF pathway in pancreatic NET are warranted.

 

Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O'Reilly EM, Meyerhardt JA, Venook A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocrine-Related Cancer 29: 335-44, 2022.